Cargando…

Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study

BACKGROUND: Owing to its variable course from asymptomatic cases to sudden death risk stratification is of paramount importance in newly diagnosed non-ischemic cardiomyopathy. We tested whether late gadolinium enhancement (LGE) assessed by cardiac magnetic resonance (CMR) imaging is a prognostic mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Karin A. L., Müller, Iris, Kramer, Ulrich, Kandolf, Reinhard, Gawaz, Meinrad, Bauer, Axel, Zuern, Christine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577793/
https://www.ncbi.nlm.nih.gov/pubmed/23437315
http://dx.doi.org/10.1371/journal.pone.0057077
_version_ 1782259973776998400
author Müller, Karin A. L.
Müller, Iris
Kramer, Ulrich
Kandolf, Reinhard
Gawaz, Meinrad
Bauer, Axel
Zuern, Christine S.
author_facet Müller, Karin A. L.
Müller, Iris
Kramer, Ulrich
Kandolf, Reinhard
Gawaz, Meinrad
Bauer, Axel
Zuern, Christine S.
author_sort Müller, Karin A. L.
collection PubMed
description BACKGROUND: Owing to its variable course from asymptomatic cases to sudden death risk stratification is of paramount importance in newly diagnosed non-ischemic cardiomyopathy. We tested whether late gadolinium enhancement (LGE) assessed by cardiac magnetic resonance (CMR) imaging is a prognostic marker in consecutive patients with newly diagnosed non-ischemic cardiomyopathy. METHODS: We enrolled 185 patients who presented for evaluation of newly diagnosed non-ischemic cardiomyopathy. Coronary artery disease was excluded by coronary angiography. Following risk markers were additionally assessed: NYHA functional class (≥II), brain natriuretic peptide (>100 ng/l), troponin I (TnI, ≥0.03 µg/l), left ventricular ejection fraction (LVEF, ≤40%), left ventricular enddiastolic diameter (>55 mm) and QRS duration (>98 ms). Endpoint of the study was the composite of all-cause mortality, heart transplantation, aborted sudden death, sustained ventricular tachycardia or hospitalization due to decompensated heart failure within three years of follow-up. RESULTS: During median follow-up of 21 months, 54 patients (29.2%) reached the composite endpoint. Ninety-four of the 185 patients (50.8%) were judged LGE-positive. Prognosis of LGE-positive patients was significantly worse than that of LGE-negative patients (cumulative 3-year event rates of 67.4% in LGE-positive and 27.2% in LGE-negative patients, respectively; p = 0.021). However, in multivariable analysis, presence of LGE was not an independent predictor of outcome. Only LVEF ≤40% and TnI ≥0.03 µg/l were independent risk predictors of the composite endpoint yielding relative risks of 3.9 (95% CI 1.9–8.1; p<0.0001) and 2.2 (95% CI 1.2–4.0; p = 0.014), respectively. CONCLUSIONS: In consecutive patients presenting with newly diagnosed non-ischemic cardiomyopathy, LGE-positive patients had worse prognosis. However, only traditional risk parameters like left ventricular performance and cardiac biomarkers but not presence of LGE were independent risk predictors.
format Online
Article
Text
id pubmed-3577793
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35777932013-02-22 Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study Müller, Karin A. L. Müller, Iris Kramer, Ulrich Kandolf, Reinhard Gawaz, Meinrad Bauer, Axel Zuern, Christine S. PLoS One Research Article BACKGROUND: Owing to its variable course from asymptomatic cases to sudden death risk stratification is of paramount importance in newly diagnosed non-ischemic cardiomyopathy. We tested whether late gadolinium enhancement (LGE) assessed by cardiac magnetic resonance (CMR) imaging is a prognostic marker in consecutive patients with newly diagnosed non-ischemic cardiomyopathy. METHODS: We enrolled 185 patients who presented for evaluation of newly diagnosed non-ischemic cardiomyopathy. Coronary artery disease was excluded by coronary angiography. Following risk markers were additionally assessed: NYHA functional class (≥II), brain natriuretic peptide (>100 ng/l), troponin I (TnI, ≥0.03 µg/l), left ventricular ejection fraction (LVEF, ≤40%), left ventricular enddiastolic diameter (>55 mm) and QRS duration (>98 ms). Endpoint of the study was the composite of all-cause mortality, heart transplantation, aborted sudden death, sustained ventricular tachycardia or hospitalization due to decompensated heart failure within three years of follow-up. RESULTS: During median follow-up of 21 months, 54 patients (29.2%) reached the composite endpoint. Ninety-four of the 185 patients (50.8%) were judged LGE-positive. Prognosis of LGE-positive patients was significantly worse than that of LGE-negative patients (cumulative 3-year event rates of 67.4% in LGE-positive and 27.2% in LGE-negative patients, respectively; p = 0.021). However, in multivariable analysis, presence of LGE was not an independent predictor of outcome. Only LVEF ≤40% and TnI ≥0.03 µg/l were independent risk predictors of the composite endpoint yielding relative risks of 3.9 (95% CI 1.9–8.1; p<0.0001) and 2.2 (95% CI 1.2–4.0; p = 0.014), respectively. CONCLUSIONS: In consecutive patients presenting with newly diagnosed non-ischemic cardiomyopathy, LGE-positive patients had worse prognosis. However, only traditional risk parameters like left ventricular performance and cardiac biomarkers but not presence of LGE were independent risk predictors. Public Library of Science 2013-02-20 /pmc/articles/PMC3577793/ /pubmed/23437315 http://dx.doi.org/10.1371/journal.pone.0057077 Text en © 2013 Müller et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Müller, Karin A. L.
Müller, Iris
Kramer, Ulrich
Kandolf, Reinhard
Gawaz, Meinrad
Bauer, Axel
Zuern, Christine S.
Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title_full Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title_fullStr Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title_full_unstemmed Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title_short Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study
title_sort prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577793/
https://www.ncbi.nlm.nih.gov/pubmed/23437315
http://dx.doi.org/10.1371/journal.pone.0057077
work_keys_str_mv AT mullerkarinal prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT mulleriris prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT kramerulrich prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT kandolfreinhard prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT gawazmeinrad prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT baueraxel prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy
AT zuernchristines prognosticvalueofcontrastenhancedcardiacmagneticresonanceimaginginpatientswithnewlydiagnosednonischemiccardiomyopathycohortstudy